ライフサイエンスコーパス: red marrow

1 e to be in the liver and spleen (besides the red marrow).

2 ptake and underestimate the absorbed dose to red marrow.

3 from the specific activity concentration in red marrow.

4 transferrin transport of (177)Lu back to the red marrow.

5 ulate radiation absorbed doses to organs and red marrow.

6 s that delivered identical absorbed doses to red marrow.

7 268 mCi), based on the radiation dose to the red marrow.

8 med maximum tolerated dose of 450 cGy to the red marrow.

9 based on a prescribed radiation dose to the red marrow.

10 y multiples of 24 in the kidneys, 1.8 in the red marrow, 0.65 in the liver, 0.077 in the intestinal w

11 90)Y-DOTA-BC8 were 0.35 +/- 0.20 cGy/MBq for red marrow, 0.80 +/- 0.24 cGy/MBq for liver, 3.0 +/- 1.4

12 es were as follows: 2.7 mGy, liver; 2.1 mGy, red marrow; 1.7 mGy, testes; and 1.9 mGy, ovaries.

13 Consequently, significantly lower red marrow (2.1 +/- 1.0 cGy/mCi versus 4.3 +/- 1.6 cGy/m

14 rapeutic doses delivering 150-450 cGy to the red marrow (70-296 mCi) and six patients had more than o

15 , followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq).

16 , followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04mSv/MBq).

17 The contribution to red marrow absorbed dose from beta-emitting radionuclide

18 Calculated red marrow absorbed dose in patients receiving radioimmu

19 of administered activity and whole-body and red marrow-absorbed dose.

20 In this study, we directly estimated red marrow activity concentration and the self-dose comp

21 ere drawn over several lumbar vertebrae, and red marrow activity concentration was quantified.

22 inder of the body is much higher than in the red marrow and a different correction is needed.

23 In infancy, bone marrow is mostly red marrow and converts to fatty yellow marrow in a syst

24 g the number of cycles based on BED(max) for red marrow and kidneys, and a treatment having 4 cycles

25 abeled antibodies, which does not compromise red marrow and may allow, for some patients, a substanti

26 With acceptable red marrow and organ dose, radioimmunotherapy is an opti

27 absorbed fraction for total body irradiating red marrow and other skeletal tissues is the inverse of

28 of time-independent proportionality between red marrow and plasma activity concentration may be too

29 The doses to the red marrow and spleen were 0.00797 mGy/MBq (0.0295 rad/m

30 The red marrow and the kidneys (BED(max) of 2 Gy(15) and 40

31 and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.

32 etention time in liver, spleen, kidneys, and red marrow, and the highest absorbed doses were in splee

33 Activity concentrations in plasma and red marrow (assuming a plasmacrit of 0.58, an extracellu

34 Initial uptake in red marrow averaged 23% +/- 11% and cleared with a biolo

35 dose component of absorbed radiation dose to red marrow based on PET/CT of 2 different (124)I-labeled

36 Absorbed doses (whole body and red marrow) based on the simulated (177)Lu-cG250 data co

37 , considering the additional constraint of a red marrow BED less than 1 Gy15, was individually quanti

38 mpartment model intended to establish a pure red marrow biodistribution by separating the nonspecific

39 we determined the tumor, liver, spleen, and red marrow biologically effective doses (BEDs) for a max

40 dence times for (11)C-nicotine in the liver, red marrow, brain, and lungs were 0.048 +/- 0.010, 0.031

41 a reverse process of natural replacement of red marrow by yellow marrow.

42 TNF-transgenic mice are caused by yellow to red marrow conversion, with increased myelopoiesis and i

43 were calculated using 2 different methods of red marrow cumulated activity and red marrow-to-blood ac

44 Among all tissues, the red marrow demonstrated the highest residence time.

45 5), whole-body absorbed dose (r = 0.65), and red marrow dose (r = 0.62 and 0.75).

46 and there was a good correlation between the red marrow dose and myelotoxicity.

47 All red marrow dose calculation schemes resulted in essentia

48 The mean red marrow dose estimated for the 90Y-hMN-14 IgG was 1.6

49 e used to accurately scale reference patient red marrow dose estimates and that these dose estimates

50 a mean kidney dose of 3.47 +/- 1.40 Gy/GBq, red marrow dose of 0.11 +/- 0.04 Gy/GBq, and salivary gl

51 sulted in < or = grade 2 myelotoxicity and a red marrow dose of 450 cGy resulted in reversible grade

52 Because patients receiving the same red marrow dose often experience different grades of tox

53 The highest correlation observed was between red marrow dose or total body dose and 1/PN (r = 0.86).

54 The tumor-to-red marrow dose ratio was higher for radioimmunotherapy

55 Tumor/red marrow dose ratios exceeded 3:1 for most lesions.

56 umor uptakes (p = 0.02), as well as tumor-to-red marrow dose ratios, than other cancer types.

57 Using an unadjusted red marrow dose to predict toxicity >/= grade 3, there w

58 Red marrow dose, baseline blood counts, multiple bone or

59 ting toxicity among the following variables: red marrow dose, baseline platelet and WBC counts, bone

60 Red marrow dose, baseline platelet or WBC counts and mul

61 However, using a FLT3-L-adjusted red marrow dose, there were 8 true-positives, but only 2

62 Red marrow doses < or = 250 cGy resulted in < or = grade

63 d kidney doses of approximately 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gland dose

64 Red marrow doses of up to 350 cGy generally could be del

65 Red marrow doses ranged from 45 to 706 cGy, and whole-bo

66 m the compartment model were used to perform red marrow dosimetry at each skeletal site.

67 The red marrow elimination phase was statistically slower in

68 8 rad/mCi; range, 15.02-37.07 rad/mCi), with red marrow estimates on the order of 3.32 rad/mCi (range

69 uoted for the absorbed dose delivered to the red marrow following marrow-localizing radiolabeled anti

70 Fatty infiltration of haematopoietic red marrow follows irradiation or chemotherapy and is a

71 If patients with diffuse red marrow infiltration and extensive chemotherapeutic p

72 r a range of organs including bone surfaces, red marrow, kidneys, gut, and whole body using scintigra

73 doses (cGy/mCi) delivered to the total body, red marrow, lungs, liver, spleen and kidneys were 0.5 +/

74 The S-value methodology assumes a fixed red marrow mass as defined by the standard Medical Inter

75 oduced in marrow radiation estimates because red marrow mass varies from patient to patient.

76 Single cell suspensions from the red marrow of the long bones were cultured 14 days in vi

77 in the epiphysis, metaphysis, diaphysis, and red marrow of the tibia was obtained.

78 use of this measurement to adjust calculated red marrow or total body radiation doses may provide sig

79 ed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therape

80 sicles, CB ossicles showed a predominance of red marrow over yellow marrow, as demonstrated by histom

81 toxicity did not correlate with estimates of red marrow radiation absorbed dose, total-body radiation

82 t body weight, total body radiation dose, or red marrow radiation dose and PTG, PPD, PN, and 1/PN.

83 The red marrow radiation doses (cGy) were adjusted for the p

84 FLT3-L-adjusted red marrow radiation doses provide improved correlation

85 Red marrow radiation doses were determined for 30 patien

86 Accurate determination of red marrow radiation is important because myelotoxicity

87 r of recovery of progenitor cells and, thus, red marrow radiosensitivity (because during the recovery

88 h the urinary bladder, osteogenic cells, and red marrow receiving the highest doses at 0.080, 0.077,

89 In addition, red marrow reconversion from fatty yellow marrow wherein

90 ading to active uptake in the radiosensitive red marrow region where these cells are located.

91 0.0074 rad/mCi) for the ovaries, testes, and red marrow, respectively.

92 0.04 mGy/MBq delivered to the whole-body and red marrow, respectively.

93 When using the blood-based model of red marrow (RM) absorbed dose estimation, there are only

94 een Monte Carlo-derived absorbed dose to the red marrow (RM) and hematologic toxicity in patients bei

95 Red marrow (RM) is often the primary organ at risk in ra

96 llows for image-based estimates of organ and red marrow (RM) residence times.

97 Estimates of radiation absorbed dose to the red marrow (RM) would be valuable in treatment planning

98 Plasma-based estimates of red marrow self-dose tended to be greater than image-bas

99 latively increased renal and hepatic uptake, red marrow suppression is the only DLT of 188Re-MN-14.

100 Red marrow suppression was the only DLT observed.

101 Red marrow suppression was the only observed toxicity an

102 The S value assigned to the red marrow target region from activity distributed in th

103 glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% alpha, 0.5% beta,

104 nd multiple skeletal sites presumed to house red marrow: the T9-L5 vertebrae and the ilium portion of

105 rotocol that could show an improved tumor-to-red marrow therapeutic ratio compared with conventional

106 methods of red marrow cumulated activity and red marrow-to-blood activity concentration ratio determi

107 The red marrow-to-plasma activity concentration ratio (RMPR)

108 The average tumor-to-red marrow, tumor-to-liver, tumor-to-lungs, and tumor-to

109 splenic uptake (7.7% +/- 1.0% ad. dose) and red marrow uptake (14 +/- 1.8%) were lower than those of

110 onclusion: Our results suggest that specific red marrow uptake of [(177)Lu]Lu-DOTATATE is in line wit

111 tudy aimed to identify and quantify specific red marrow uptake using SPECT/CT images collected after

112 The mean specific red marrow uptake was 49% (range, 0%-93%) higher than th

113 ent of the S value from remainder tissues to red marrow using either MIRD 11 or MIRDOSE3.

114 Thresholds for "normal" red marrow versus pathologic BME were established, and i

115 gan (0.200 mGy/MBq), whereas the dose to the red marrow was 0.006 mGy/MBq.

116 he median (+/-SD) total absorbed dose to the red marrow was 0.056 +/- 0.023 Gy/GBq and 0.043 +/- 0.02

117 ponent of the absorbed radiation dose to the red marrow was estimated from the images, from the plasm

118 The red marrow was found to be the dose-limiting organ for a

119 The mean absorbed doses for kidneys and red marrow were 1.0 +/- 0.6 Gy/GBq (range, 0.4-2.0 Gy/GB

120 The mean absorbed doses for kidneys and red marrow were 1.0 0.6 Gy/GBq (range, 0.4-2.0 Gy/GBq) a

121 he ranges of absorbed doses delivered to the red marrow were 177-994 and 1-5 mGy/MBq from activity on

122 idneys, parotid glands, lacrimal glands, and red marrow were 23, 16, 70, and 1 Gy, respectively.

123 Normal bone marrow is composed of red marrow, which is hematopoietically active (producing